Ariosa Diagnostics Enters 2013 with New Offering and Global Expansion
SAN JOSE, Calif., Jan. 9, 2013 /PRNewswire/ -- Ariosa Diagnostics, provider of the Harmony™ Prenatal Test, today announced plans to expand the indications for the Harmony test and broaden access into new, significant global markets.
The Harmony test analyzes cell-free DNA circulating in maternal blood, which allows a high level of accuracy for detecting fetal trisomies, such as trisomy 21 that causes Down syndrome. Ariosa is expanding the clinical indications for the Harmony test to include all IVF singleton pregnancies, including unrelated egg donor and surrogate pregnancies.
The expanded Harmony test for IVF pregnancies will be available in the United States, as well as in several international markets. In 2012, Ariosa entered the European market as the first non-invasive prenatal test in the United Kingdom. Ariosa is now expanding throughout Europe, the Middle East, Australia, and Latin America.
"We are focused on identifying those test enhancements which can provide clear clinical utility," said Ariosa CEO Ken Song, MD. "The Harmony test represents a major clinical advance to provide reliable and accurate information to pregnant women, and we are committed to making this test available globally."
About Ariosa Diagnostics
Ariosa Diagnostics, Inc. is a molecular diagnostics company committed to innovating together to improve patient care. The flagship product, the Harmony Prenatal Test, is a safe, highly accurate and affordable prenatal test for maternal and fetal health. Led by an experienced team, Ariosa is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. The Harmony Prenatal Test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.
The company began operations in 2010 and is headquartered in San Jose, Calif. For more information, visit www.ariosadx.com.
SOURCE Ariosa Diagnostics